# Shanghai Applied Protein Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-applied-protein-technology-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.aptbiotech.com
- Total disclosed funding: $28M
- Latest round: Series C (Apr 7, 2024)
- Investors on record: 5

## About

Established in 2004 and based in Shanghai, China, the company is headquartered in Shanghai and has built innovative technology centers, data centers and clinical testing centers in Shanghai, Yiwu and Taizhou, with a total area of over 20,000?, and formerly known as the Proteome Research and Analysis Center (SIBS) of Shanghai Institutes for Biological Sciences, CAS. It was one of the first platforms to participate in international HLPP (liver) and HPPP (plasma) projects, and has obtained CMA metrology certification and Dun & Bradstreet certification. The company has also published hundreds of papers in SCI journals and obtained dozens of invention patents and copyrights. In April 2024, the firm closed a series C funding.

In the field of mass spectrometry multi-omics precision medical applications, the company has established three service platforms for scientific and technical services (protein/modification/metabolism research), biomedical characterization and confirmation, and precision medicine. Through these platforms, the company provides services such as high-throughput sequencing - genome sequencing, proteome - quantitative proteome iTRAQ (isobaric tags for relative and absolute quantitation, an in vitro peptide labeling technology), Single cell sequencing, etc.

The company’s revenue is generated by providing three major service platforms: scientific and technological services (protein/modification/metabolism research), biomedical characterization and verification, and precision medicine.

The company will use the series C funding for accelerated development of innovative products based on multi-omics application scenarios and global market expansion.

## Funding rounds

- Series C, Apr 7, 2024 — GF Xinde Investment, Shanghai Sun Rock Capital Management
- Series B, Aug 17, 2022 — Legend Capital
- Series A, Apr 22, 2020, $28M — Shandong High-tech Investment Corporation, Jinkong Qiyuan Capital

## Investors

- Shandong High-tech Investment Corporation (https://capitalatlas.ai/funds/shandong-high-tech-investment-corporation) — Series A
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series A
- Legend Capital — Series B
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series C
- Shanghai Sun Rock Capital Management (https://capitalatlas.ai/funds/shanghai-sun-rock-capital-management) — Series C